Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in elderly patients with major depressive disorder (MDD).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of major depressive disorder according to the DSM-IV-TR (Text Revision of the Diagnostic and Statistical Manual of Mental Disorders version-4) criteria for any of the following:

  * In case of not receiving antidepressant treatment: Patients with a diagnosis within 6 months prior to provision of written informed consent
  * In case of receiving antidepressant treatment: Patients continuously receiving antidepressant treatment at the time of providing written informed consent
* Female patients of childbearing potential with a negative serum pregnancy test result and who were willing and able to use a reliable method of birth control during the study
* Patients who could understand and comply with the requirements of the study, as judged by the investigator/sub-investigator

Exclusion Criteria:

* A current or past history of a DSM-IV-TR Axis I disorder other than major depressive disorder within 6 months prior to the study
* Diagnosis of a DSM-IV-TR Axis II disorder that was considered to have a major impact on the patient's current psychiatric status
* A history of substance or alcohol abuse or dependence excluding caffeine and nicotine
* Patients who were unable to abstain from drugs that induce or inhibit the drug-metabolizing enzyme CYP3A4 from 14 days prior to the start of study drug administration and throughout the study period
* Patients showing evidence or signs of renal or hepatic failure, serious heart disease, cerebrovascular disease, viral hepatitis B or C, or acquired immunodeficiency syndrome (AIDS) (carrier)
* Patients with any diagnosis of a neurological condition, such as Parkinson's disease, Huntington's disease, essential tremor, multiple sclerosis, prior brain injury, space occupying lesion, etc.
* A clinical finding that is unstable (e.g., hypertension, unstable angina) or that, in the opinion of the investigator or sub-investigator, would be negatively affected by the study medication or that would affect the study medication
* A current diagnosis of cancer (except basal or squamous cell skin carcinoma), unless it has been in remission for at least 5 years.
* Conditions that could affect absorption and metabolism of study medication (e.g., malabsorption syndrome, liver disease).
* A current or past diagnosis of transient ischemic attack (TIA)
* A history of seizure disorder, except for febrile convulsions
* Receipt of electroconvulsive therapy within 90 days prior to the start of study drug administration
* Use of a depot antipsychotic injection and inability to be off the drug for a period of twice the dosing interval prior to the start of study drug administration and throughout the study period
* Patients who, in the investigator's opinion, would require psychotherapy (other than supportive psychotherapy) during the study period, unless psychotherapy had been ongoing for a minimum of 90 days

before study drug administration

* A score of ≥ 3 on the HAM-D17 Item (suicide) or a suicide attempt within the past 6 months, and those judged to be at serious suicidal or homicidal risk in the opinion of the investigator/sub-investigator
* A current or past history of diabetes mellitus\* or glycated hemoglobin (HbA1c) of ≥ 6.5% at screening within 2 months before the start of study drug administration (\*refer to the guidelines for monitoring blood glucose levels in patients treated with atypical antipsychotics)
* A white blood cell count (WBC) of ≤ 3,000/mm3 at screening assessment
* Elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values at screening assessment (grade 2 or higher according to the "Criteria for Classification of the Grade of Adverse Drug Reactions to Pharmaceutical Products" (Pharmaceutical Affairs Bureau Safety Division's Notification No. 80 issued on 29 June 1992))
* A known history of hypersensitivity to quetiapine or to any other component in the FK949E tablets at the time of providing written informed consent
* Treatment with quetiapine for depressive symptoms or bipolar disorder (mania) at the time of providing written informed consent
* Participation in another clinical study or post-marketing study within 12 weeks prior to the start of study drug administration